Design, Synthesis, and Biological Activity Evaluation of Deuterated Diphenyl Azole Alcohol-Based CYP51 Inhibitors
Journal of Medicinal Chemistry · 12.06.2025 · 68 (11) · 12229-12257
DOI: 10.1021/acs.jmedchem.5c01068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 03.06.2025. Verfasst von Yixiang Sun und 14 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical Uni…. Hauptthemen laut MEDLINE: Antifungal Agents, Drug Design, Azoles, 14-alpha Demethylase Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Program of Innovative Research Team of the Ministry of Education, Program of Liaoning Innovative Research Team in University.
Abstract (Originalsprache)
In recent years, the incidence of invasive fungal infections (IFIs) has risen significantly, leading to increased clinical use of azole antifungals. However, their therapeutic utility remains limited by emerging drug resistance, inadequate oral bioavailability, and adverse effects. This study focused on optimizing in vivo pharmacokinetic properties through a molecular hybridization strategy, integrating structural features of Oteseconazole and A33. After multiple rounds of structural refinement, a series of deuterated biphenyl aryl azolol derivatives were developed. Compound C52 demonstrated potent broad-spectrum antifungal activity in vitro, antibiofilm properties, and inhibition of fungal morphological transition. Notably, it exhibited favorable pharmacokinetic characteristics, with an oral bioavailability (F) of 63.4%. In vivo efficacy studies revealed that the compound significantly prolonged survival in murine models and maintained potent activity against drug-resistant strain 17#. These findings position compound C52 as a promising CYP51-targeting candidate for treating IFIs, establishing a robust chemical foundation for developing next-generation antifungal therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe, Shenyang 110016, China.
- The School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe, Shenyang 110016, China.
- The School of life Science and Biopharmaceutical, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe, Shenyang 110016, China.
- Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Hainan University, Haikou 570228, China.
ORCID-Profile: Dongmei Zhao
Förderung
- National Natural Science Foundation of China
- Program of Innovative Research Team of the Ministry of Education
- Program of Liaoning Innovative Research Team in University
Zitieren
APA
Sun, Y., Luo, Z., Li, K., Wang, H., Gao, Z., Zhang, J., Liu, R., Liu, R., Wu, X., Liu, N., Zhang, H., Su, X., Yin, W., Zhao, D., & Cheng, M. (2025). Design, Synthesis, and Biological Activity Evaluation of Deuterated Diphenyl Azole Alcohol-Based CYP51 Inhibitors. Journal of Medicinal Chemistry, 68(11), 12229-12257. https://doi.org/10.1021/acs.jmedchem.5c01068
Vancouver
Sun Y, Luo Z, Li K, Wang H, Gao Z, Zhang J, et al. Design, Synthesis, and Biological Activity Evaluation of Deuterated Diphenyl Azole Alcohol-Based CYP51 Inhibitors. Journal of Medicinal Chemistry. 2025;68(11):12229-12257. doi:10.1021/acs.jmedchem.5c01068
BibTeX
@article{Sun2025,
author = {Sun, Yixiang and Luo, Zirui and Li, Kejian and Wang, Hongjian and Gao, Zixuan and Zhang, Jiachen and Liu, Rongrong and Liu, Rui and Wu, Xudong and Liu, Nian and Zhang, Haoyu and Su, Xin and Yin, Wenbo and Zhao, Dongmei and Cheng, Maosheng},
title = {Design, Synthesis, and Biological Activity Evaluation of Deuterated Diphenyl Azole Alcohol-Based CYP51 Inhibitors},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {11},
pages = {12229--12257},
doi = {10.1021/acs.jmedchem.5c01068}
}
EUVIMED